1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €16.97 (+116.18%). The median is €15.53 (+97.83%).
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -853.43 | 1.09% |
| Net profit | -10.01M | 110.32% |
| EBITDA | -10.39M | 92.33% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €9.63M |
Number of shares | 1.29M |
52-week high/low | €11.56 - €4.58 |
| Dividends | No |
Beta | 1.17 |
P/E ratio | -4.45 |
PEG ratio | -0.70 |
P/B ratio | 3.04 |
P/S ratio | 0.00 |
Company profile
| Name | Satellos Bioscience |
| CEO | Francis Gleeson |
| Employees | 18 |
Discover assets
Shareholders of Satellos Bioscience also invest in the following assets
